Memphasys (ASX:MEM) has reached a major commercial milestone with the Therapeutic Goods Administration granting approval for its Felix System ahead of schedule, clearing the way for immediate sales and clinical deployment across Australia.
Memphasys fast-tracks Australian market entry with early TGA approval for Felix system
February 10, 2026 Australian Biotech
Latest Video
New Stories
-
Has any patient ever said they accept a rejection because of the Kaplan-Meier curve?
August 17, 2026 - - Latest News -
Pharmac aims to pivot toward faster process and broader value framework
August 17, 2026 - -
The 'Dispatched' Podcast - Series 5. Ep.28
August 16, 2026 - - Podcast -
Melbourne biotech pursues an oral path to changing Type 1 diabetes
August 14, 2026 - - Australian Biotech -
A plain language version of these dreadful and useless documents
August 14, 2026 - - Latest News -
An institution dominated by very clever people, but where is the wisdom?
August 14, 2026 - - Latest News -
CUREator+ backs six Australian startups with $13.5 million to advance new health technologies
August 13, 2026 - - Australian Biotech

